Skip to main content

Table 2 Relationship between CD16 expression on CD11b+myeloid cells after capecitabine therapy and clinicopathologic characteristics

From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

Characteristics All patients (n = 134) CD16+ after therapy (n = 65, 48.51%) CD16low/− after therapy (n = 69, 51.49%) P value
n % n % n %
Age (years)
 <65 70 52.24% 36 51.43% 34 48.57% 0.479
 ≥65 64 47.76% 29 45.31% 35 54.69%  
Gender
 Male 82 61.19% 42 51.22% 40 48.78% 0.43
 Female 52 38.81% 23 44.23% 29 55.77%  
Tumor location
 Rectum 68 50.75% 32 47.06% 36 52.94% 0.733
 Colon 66 49.25% 33 50.00% 33 50.00%  
Tumor Size
 ≥5 cm 57 42.54% 25 43.86% 32 56.14% 0.354
 <5 cm 77 57.46% 40 51.95% 37 48.05%  
CEA level after therapy
 ≤5 ng/ml 114 85.07% 60 52.63% 54 47.37% 0.023
 >5 ng/ml 20 14.93% 5 25.00% 15 75.00%  
CA199 level after therapy
 ≤27 ng/ml 116 86.57% 61 52.59% 55 47.41% 0.016
 >27 ng/ml 18 13.43% 4 22.22% 14 77.78%  
TNM stage (AJCC)
 Stage II 98 73.13% 45 45.92% 53 54.08% 0.322
 Stage III 36 26.87% 20 55.56% 16 44.44%  
Location of recurrence
 Loco-regional 3 13.04% 2 40.00% 1 5.56% 0.042
 liver + lung 3 13.04% 2 40.00% 1 5.56%  
 liver 10 43.48% 1 20.00% 9 50.00%  
 lung 6 26.09% 0 0.00% 6 33.33%  
 peritoneum 1 4.35% 0 0.00% 1 5.56%